The CD1c (BDCA-1) antigen belongs to the CD1 family and is involved in presentation of lipid antigens. In human blood, CD1c (BDCA-1) is exclusively expressed on CD11chigh CD123low myeloid dendritic cells and a small subpopulation of CD19+ B cells.1
Myeloid dendritic cells represent the major subset of dendritic cells in human peripheral blood (about 0.3% of white blood cells). They display a strong T cell stimulatory and cross-presenting capacity.2–4
The CliniMACS CD1c (BDCA-1)-Biotin Product Line consists of murine anti-CD1c (BDCA-1) monoclonal antibodies conjugated to biotin.
One vial contains 5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD1c (BDCA-1)-Biotin Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.
The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE).
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use.
The CliniMACS CD1c (BDCA-1)-Biotin Product Line was developed for the enrichment of CD1c (BDCA-1)+ myeloid dendritic cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.
After labeling of target cells with the CliniMACS CD1c (BDCA-1)-Biotin, the CliniMACS Anti-Biotin Reagent is used for the magnetic enrichment of CD1c (BDCA-1)+ cells from the cellular product. A CD19+ B cell depletion is recommended prior to the enrichment of CD1c (BDCA-1)+ cells, due to expression of CD1c (BDCA-1) on a subset of CD19+ B cells.
CD1c (BDCA-1) enriched blood MDCs were used in clinical studies for the treatment of melanoma and prostate cancer.5,6
Flow cytometric analysis of CD19-depleted cells (B) followed by the analysis of CD1c (BDCA-1)- enriched cells (C) using the CliniMACS CD19 System, CliniMACS CD1c (BDCA-1)-Biotin System and CliniMACS Anti-Biotin System in combination.
Flow cytometric analysis of CD1c (BDCA-1)+ cell enrichment
After CD19 depletion
After CD19 depletion and CD1c (BDCA-1) enrichment
- Dzionek, A. et al. (2000) BDCA-2, BDCA-3, BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165: 6037–6046.
- Jefford, M. et al. (2003) Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 102: 1753–1763.
- Schnurr et al. (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465–2472.
- Kvale et al. (2006) CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood 107: 2022–2029.
- Prue et al. (2007) 5th Int. meeting on DC vaccination and other strategies to tip the balanced of the immune system(poster): P090.
- Davis et al. (2005) 96th Annual Meeting of the AACR(poster): 3466.
Please follow this link
to search for certificates by lot number.